Crystallization (Comment) | Organism |
---|---|
molecular modeling of complexes with inhibitors, e.g. 6-([2-[(4-cyanophenyl)amino]pyrimidin-4-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile, 6-([4-[(4-cyanophenyl)amino]-1,3,5-triazin-2-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile | Human immunodeficiency virus 1 |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
6-([2-[(4-cyanophenyl)amino]pyrimidin-4-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile | compound has potency below 10 nM towards wild-type HIV-1 and viral variants containing the clinically important Y181C and K103N/Y181C mutations, greater activity than efavirenz particularly towards the K103N-bearing variant, normal cytotoxicity, and solubility | Human immunodeficiency virus 1 | |
6-([4-[(4-cyanophenyl)amino]-1,3,5-triazin-2-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile | compound has potency below 10 nM towards wild-type HIV-1 and viral variants containing the clinically important Y181C and K103N/Y181C mutations, greater activity than efavirenz particularly towards the K103N-bearing variant, normal cytotoxicity, and solubility | Human immunodeficiency virus 1 |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Human immunodeficiency virus 1 | - |
- |
- |